263 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Compass Financial Services Inc

Compass Financial Services Inc acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 263 shares of the medical research company’s stock, valued at approximately $69,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. AMF Tjanstepension AB increased its holdings in Amgen by 16.9% in the 3rd quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock valued at $38,825,000 after acquiring an additional 17,387 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt grew its position in shares of Amgen by 33.8% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 47,318 shares of the medical research company’s stock valued at $15,240,000 after purchasing an additional 11,954 shares in the last quarter. Wynn Capital LLC increased its holdings in shares of Amgen by 1.6% in the third quarter. Wynn Capital LLC now owns 6,528 shares of the medical research company’s stock worth $2,103,000 after purchasing an additional 103 shares during the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH increased its holdings in shares of Amgen by 3.2% in the third quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 5,069 shares of the medical research company’s stock worth $1,633,000 after purchasing an additional 159 shares during the last quarter. Finally, First Affirmative Financial Network lifted its position in shares of Amgen by 128.7% in the third quarter. First Affirmative Financial Network now owns 3,176 shares of the medical research company’s stock worth $1,023,000 after buying an additional 1,787 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 1.4 %

Shares of AMGN opened at $293.54 on Friday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.96. The firm has a market capitalization of $157.79 billion, a price-to-earnings ratio of 38.88, a PEG ratio of 3.01 and a beta of 0.56. The company has a 50-day moving average of $272.26 and a 200 day moving average of $303.21. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, research analysts expect that Amgen Inc. will post 20.59 EPS for the current year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.24%. Amgen’s dividend payout ratio is presently 119.21%.

Analyst Ratings Changes

Several equities analysts have weighed in on AMGN shares. Royal Bank of Canada restated an “outperform” rating and set a $324.00 price target on shares of Amgen in a report on Friday, January 24th. Piper Sandler Companies reissued an “overweight” rating and issued a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Wells Fargo & Company decreased their price target on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a research note on Friday, January 10th. Redburn Partners dropped their price objective on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Finally, Wolfe Research started coverage on shares of Amgen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $313.23.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.69% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.